Logo image
Back
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole
Journal article   Open access   Peer reviewed

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

M A Pfaller, L Boyken, R J Hollis, S A Messer, S Tendolkar and D J Diekema
Journal of clinical microbiology, Vol.43(11), pp.5425-5427
11/2005
DOI: 10.1128/JCM.43.11.5425-5427.2005
PMCID: PMC1287823
PMID: 16272464
url
https://doi.org/10.1128/JCM.43.11.5425-5427.2005View
Published (Version of record) Open Access

Abstract

Anidulafungin is an echinocandin antifungal agent with potent activity against Candida spp. We assessed the in vitro activity of anidulafungin against 2,235 clinical isolates of Candida spp. using the CLSI broth microdilution method. Anidulafungin was very active against Candida spp. (the MIC at which 90% of strains are inhibited [MIC(90)] was 2 microg/ml when MIC endpoint criteria of partial inhibition [MIC-2] were used). Candida albicans, C. glabrata, C. tropicalis, C. krusei, and C. kefyr were the most susceptible species of Candida (MIC(90), 0.06 to 0.12 microg/ml), and C. parapsilosis, C. lusitaniae, and C. guilliermondii were the least susceptible (MIC(90), 0.5 to 2 microg/ml). In addition, 315 fluconazole-resistant isolates were tested, and 99% were inhibited by < or =1 microg/ml of anidulafungin. These results provide further evidence for the spectrum and potency of anidulafungin activity against a large and geographically diverse collection of clinically important isolates of Candida spp.
 Antifungal Agents - pharmacology Fluconazole - pharmacology Candidiasis - drug therapy Humans Echinocandins Peptides, Cyclic - pharmacology Candida - drug effects Candidiasis - microbiology Drug Resistance, Fungal Microbial Sensitivity Tests - methods

Details

Metrics

19 Record Views
136 Times Cited - Web of Science
Logo image